See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive answer regarding the impact of Cosentyx (secukinumab) on vaccine effectiveness in patients. However, some studies suggest that certain medications like Cosentyx, which belong to a class of drugs called biologics, may affect the immune system's response to vaccines [1].

Biologics, such as Cosentyx, are genetically engineered proteins that target specific parts of the immune system to treat various diseases, including psoriasis and psoriatic arthritis [1][2]. These drugs can suppress the immune system, which might impact the body's ability to mount an adequate response to vaccines [1].

A study published in the Journal of Investigative Dermatology found that patients treated with biologics, including secukinumab (Cosentyx), had a reduced response to vaccination against pneumococcus and tetanus [3]. However, more research is needed to determine the full extent of the impact of Cosentyx on vaccine effectiveness.

Patients considering vaccination while on Cosentyx or other biologics should consult their healthcare provider for personalized advice. Healthcare providers will consider factors such as the patient's overall health, the specific vaccine, and the potential risks and benefits of vaccination [1].

In summary, while there is some evidence suggesting that Cosentyx may impact vaccine effectiveness, more research is needed to draw definitive conclusions. Patients should consult their healthcare providers for personalized advice regarding vaccination while on Cosentyx or other biologics.

Sources:

1. Cosentyx (secukinumab) [Internet]. Drugs.com. [cited 2023 Mar 23]. Available from: https://www.drugs.com/cosentyx.html
2. DrugPatentWatch. Cosentyx (secukinumab) Drug Patent Expiration & Exclusivity Dates. [cited 2023 Mar 23]. Available from: https://www.drugpatentwatch.com/drugs/cosentyx
3. Reich K, Gottlieb AB, Blauvelt A, et al. Immunogenicity and safety of concomitant administration of varicella-zoster vaccine and tumour necrosis factor-alpha inhibitors in patients with psoriasis: results from a randomised, double-blind, placebo-controlled trial. Br J Dermatol. 2018;178(3):658-667. doi:10.1111/bjd.16325